Skip to main content
Clinical Trials/NCT04376671
NCT04376671
Completed
N/A

Quantitative EEG Markers in Mild Cognitive Impairment in Epilepsy

Mansoura University Hospital1 site in 1 country90 target enrollmentMarch 1, 2019
ConditionsEpilepsy

Overview

Phase
N/A
Intervention
Not specified
Conditions
Epilepsy
Sponsor
Mansoura University Hospital
Enrollment
90
Locations
1
Primary Endpoint
Mini-mental state examination (MMSE)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Epileptic patients are plighted with limited daily activities, social dysfunction, family conflicts and cognitive impairment. Most of the studies had showed that cognitive disorders were frequent in patients with epilepsy.The cognitive impairment has been reported in around 25% of epileptic patients.

Detailed Description

Cognitive consequences in epilepsy are often described in the following domains: verbal memory, language, executive functions, and attention. However, most of the studies focus on one or two domains in a relatively small sample. Few studies have investigated the influential factors for the epilepsy-related cognitive impairment . However, most of these studies merely focused on one or a few potential factors and failed to consider possible distractions from other influential factors. Therefore, it is crucial to include more potential factors in the analysis and to rule out possible confounding interactions between factors.

Registry
clinicaltrials.gov
Start Date
March 1, 2019
End Date
March 1, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ahmed Esmael

Assistant Prof of Neurology

Mansoura University Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients with clinically confirmed epilepsy in adult patients.
  • Non-symptomatic epilepsy.
  • Normal CT or MRI brain, and
  • Education level of primary school at least to respond to the scales correctly were included.

Exclusion Criteria

  • Psycho-neurological illnesses,
  • History of alcoholism or drug abuse, or
  • Recently on medications that may affect cognitive functions (like antidepressants and antipsychotic drugs).

Outcomes

Primary Outcomes

Mini-mental state examination (MMSE)

Time Frame: 24 hours

This is a rapid screening tool to estimate the cognitive functions that evaluates orientation, basic attention, working memory, learning, naming, construction, comprehension, and repetition. The maximum score is 30 and scores below 24 indicating cognitive impairment.

Montreal cognitive assessment (MoCA)

Time Frame: 24 hours

Montreal cognitive assessment is a rapid sensitive screening tool for assessment of impaired cognitive function (Nasreddine et al., 2005). The main domains of MoCA scale include attention, executive functions, memory, language, attention, naming, orientation, and visual-spatial ability. The total score is 30 points. A score of 25 points or less indicated impaired cognitive function. For patients with less than12 years of education, one point was added to the total score.

Study Sites (1)

Loading locations...

Similar Trials